Skip to main content
Premium Trial:

Request an Annual Quote

French Insurer to Cover Epigenomics' Colorectal Cancer Test

NEW YORK (GenomeWeb News) – Epigenomics announced today that Swiss Life will provide insurance coverage for the firm's Epi proColon 2.0 colorectal cancer test as part of a preventive health program in France.

Swiss Life, France's third-largest private health insurer, is the first French insurer to cover the test, which uses Epigenomics' colorectal cancer biomarker Septin9 in blood plasma, and will reimburse for the test at up to 50 percent of the cost. French Social Security does not cover Epi proColon 2.0, Berlin-based Epigenomics noted.

Epigenomics CEO Geert Nygaard said in a statement that the coverage decision "clearly confirms our recently implemented commercialization approach in Europe under which we are working closely with key players in the healthcare system."

The test is CE marked in Europe, and Epigenomics is in the process of applying to the US Food and Drug Administration for marketing clearance.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.